{"id":"NHA000160","research":"hum0136","url":"https://humandbs.dbcls.jp/dataset/NHA000160","datePublished":"2021-03-05","dateModified":"2021-03-05","values":[{"key":"access-criteria","label":{"ja":"アクセス制限","en":"Access criteria"},"type":"vocabulary","terms":[{"code":"unrestricted-access","label":{"ja":"非制限公開","en":"Unrestricted-access"}}]},{"key":"type-of-data","label":{"ja":"データの種類","en":"Type of data"},"type":"text","text":{"ja":"日本人B型肝炎ワクチン（ヘプタバックス）接種者555名のGWAS統計情報","en":"GWAS for 555 Japanese individuals vaccinated with a HB vaccine (Heptavax)"}}],"experiments":[{"label":"Genotyping by array","values":[{"key":"materials-and-participants","label":{"ja":"材料と対象者","en":"Materials and participants"},"type":"text","text":{"ja":"日本人B型肝炎ワクチン（ヘプタバックス）接種者（Total：555名）\n・ワクチン低反応群（66名、HBsAb 10mIU/mL以下）\n・ワクチン中反応群（184名、HBsAb 10mIU/mL超、100 mIU/mL以下）\n・ワクチン高反応群（305名、HBsAb 100mIU/mL超）","en":"555 Japanese individuals vaccinated with a HB vaccine (Heptavax)\n- Low responders (n=66, HBsAb ≤ 10mIU/mL)\n- Intermediate responders (n=184, 10mIU/mL < HBsAb ≤ 100mIU/mL)\n- High responders (n=305, HBsAb >100mIU/mL)"}},{"key":"health-status","label":{"ja":"健康状態","en":"Health status"},"type":"vocabulary","terms":[{"code":"healthy","label":{"ja":"健常","en":"Healthy"}}]},{"key":"subject-count","label":{"ja":"対象者数","en":"Subject count"},"type":"number","numbers":[{"value":555,"unit":null,"high":null}]},{"key":"subject-count-type","label":{"ja":"対象者数の数え方","en":"Counted as"},"type":"vocabulary","terms":[{"code":"individual","label":{"ja":"人数","en":"Individual"}}]},{"key":"population","label":{"ja":"対象集団","en":"Population"},"type":"vocabulary","terms":[{"code":"japanese","label":{"ja":"日本人","en":"Japanese"}}]},{"key":"sample-description","label":{"ja":"試料説明","en":"Sample description"},"type":"text","text":{"ja":"末梢血から抽出したDNA","en":"DNAs extracted from peripheral blood cells"}},{"key":"tissue","label":{"ja":"組織","en":"Tissue"},"type":"vocabulary","terms":[{"code":"peripheral-blood","label":{"ja":"末梢血","en":"Peripheral blood"}}]},{"key":"is-tumor","label":{"ja":"腫瘍 / 非腫瘍","en":"Tumor / normal"},"type":"vocabulary","terms":[{"code":"normal","label":{"ja":"非腫瘍","en":"Normal"}}]},{"key":"sample-provider","label":{"ja":"試料の入手元","en":"Sample provider"},"type":"text","text":{"ja":null,"en":null}},{"key":"experimental-method","label":{"ja":"実験方法","en":"Experimental method"},"type":"vocabulary","terms":[{"code":"genotyping-by-array","label":{"en":"Genotyping by array"}}]},{"key":"targets","label":{"ja":"測定対象","en":"Target"},"type":"text","text":{"ja":null,"en":null}},{"key":"reagents","label":{"ja":"試薬キット","en":"Reagent kit"},"type":"vocabulary","terms":[{"code":"axiom-2-0-reagent-kit","label":{"en":"Axiom 2.0 Reagent Kit"}}]},{"key":"platform","label":{"ja":"プラットフォーム","en":"Platform"},"type":"vocabulary","terms":[{"code":"affymetrix-axiom-genome-wide-asi-1-array","label":{"en":"Affymetrix Axiom Genome-Wide ASI 1 Array"}}]},{"key":"reference-sequence","label":{"ja":"参照ゲノム","en":"Reference genome"},"type":"vocabulary","terms":[{"code":"grch37","label":{"en":"GRCh37"}}]},{"key":"filtering","label":{"ja":"QC・フィルタリング","en":"QC and filtering"},"type":"text","text":{"ja":"overall call rate < 0.95、SNP call rate < 0.95、\nHWE P < 0.001、MAF < 0.05、Regression P < 0.05","en":"overall call rate < 0.95, SNP call rate < 0.95,\nHWE P < 0.001, MAF < 0.05, Regression P < 0.05"}},{"key":"analysis-methods","label":{"ja":"解析方法","en":"Analysis method"},"type":"text","text":{"ja":"GenCall software（Genotyping Console ver. 4.2.0.26）","en":"GenCall software (Genotyping Console ver. 4.2.0.26)"}},{"key":"variant-number","label":{"ja":"バリアント数","en":"Variant count"},"type":"number","numbers":[{"value":279671,"unit":null,"high":null,"prefix":{"ja":"① 日本人ヘプタバックス接種者におけるワクチン低反応群(n=66)とワクチン反応群(n=489)を比較したGWAS結果(Imputation後): ","en":"I. GWAS for low responders (n=66) and responders (n=489) with Heptavax (after imputation): "},"suffix":{"ja":" SNPs (Figure 1a)","en":" SNPs (Figure 1a)"}},{"value":292028,"unit":null,"high":null,"prefix":{"ja":"② 日本人ヘプタバックス接種者におけるワクチン低反応群(n=66)とワクチン高反応群(n=305)を比較したGWAS結果(Imputation後): ","en":"II. GWAS for low responders (n=66) and high responders (n=305) with Heptavax (after imputation): "},"suffix":{"ja":" SNPs (Figure 1b)","en":" SNPs (Figure 1b)"}},{"value":22770,"unit":null,"high":null,"prefix":{"ja":"③ 日本人ヘプタバックス接種者におけるワクチン低反応群(n=66)とワクチン反応群(n=489)を比較したGWAS結果(Imputation前): ","en":"III. GWAS for low responders (n=66) and responders (n=489) with Heptavax (before imputation): "},"suffix":{"ja":" SNPs (Supplementary Figure 1a)","en":" SNPs (Supplementary Figure 1a)"}},{"value":23717,"unit":null,"high":null,"prefix":{"ja":"④ 日本人ヘプタバックス接種者におけるワクチン低反応群(n=66)とワクチン高反応群(n=305)を比較したGWAS結果(Imputation前): ","en":"IV. GWAS for low responders (n=66) and high responders (n=305) with Heptavax (before imputation): "},"suffix":{"ja":" SNPs (Supplementary Figure 1b)","en":" SNPs (Supplementary Figure 1b)"}},{"value":310312,"unit":null,"high":null,"prefix":{"ja":"⑤ 日本人ヘプタバックス接種者およびビームゲン接種者におけるワクチン低反応群(n=66+107)とワクチン反応群(n=489+1086)を比較したGWAS結果(Imputation後): ","en":"V. GWAS for low responders (n=66 + 107) and responders (n=489 + 1086) with Heptavax and Bimmugen (after imputation): "},"suffix":{"ja":" SNPs (Supplementary Figure 2a)","en":" SNPs (Supplementary Figure 2a)"}},{"value":317176,"unit":null,"high":null,"prefix":{"ja":"⑥ 日本人ヘプタバックス接種者およびビームゲン接種者におけるワクチン低反応群(n=66+107)とワクチン反応群(n=305+735)を比較したGWAS結果(Imputation後): ","en":"VI. GWAS for low responders (n=66 + 107) and high responders (n=305 + 735) with Heptavax and Bimmugen (after imputation): "},"suffix":{"ja":" SNPs (Supplementary Figure 2b)","en":" SNPs (Supplementary Figure 2b)"}},{"value":285687,"unit":null,"high":null,"prefix":{"ja":"⑦ 日本人ヘプタバックス接種者におけるワクチン低反応群(n=66)と日本人ビームゲン接種者におけるワクチン低反応群(n=107)を比較したGWAS結果(Imputation後): ","en":"VII. GWAS for low responders with Heptavax (n=66) and low responders with Bimmugen (n=107) (after imputation): "},"suffix":{"ja":" SNPs (Supplementary Figure 3a)","en":" SNPs (Supplementary Figure 3a)"}},{"value":312192,"unit":null,"high":null,"prefix":{"ja":"⑧ 日本人ヘプタバックス接種者におけるワクチン中反応群(n=184)と日本人ビームゲン接種者におけるワクチン中反応群(n=351)を比較したGWAS結果(Imputation後): ","en":"VIII. GWAS for intermediate responders with Heptavax (n=184) and intermediate responders with Bimmugen (n=351) (after imputation): "},"suffix":{"ja":" SNPs (Supplementary Figure 3b)","en":" SNPs (Supplementary Figure 3b)"}},{"value":321074,"unit":null,"high":null,"prefix":{"ja":"⑨ 日本人ヘプタバックス接種者におけるワクチン高反応群(n=305)と日本人ビームゲン接種者におけるワクチン高反応群(n=735)を比較したGWAS結果(Imputation後): ","en":"IX. GWAS for high responders with Heptavax (n=305) and high responders with Bimmugen (n=735) (after imputation): "},"suffix":{"ja":" SNPs (Supplementary Figure 3c)","en":" SNPs (Supplementary Figure 3c)"}}]},{"key":"policies","label":{"ja":"利用ポリシー","en":"Data use policy"},"type":"vocabulary","terms":[{"code":"nbdc-data-sharing-policy-jgap000001","label":{"ja":"NBDC データ共有ポリシー (JGAP000001)","en":"NBDC data sharing policy (JGAP000001)"}}]}]}],"fileFormats":[{"code":"xlsx","label":{"en":"XLSX"}},{"code":"zip","label":{"en":"ZIP"}}]}